Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors.

Abstract

Twenty-six patients with non-small cell carcinoma of the lung and 25 with metastatic pulmonary tumors were treated by intravenous injection of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083), a derivative of mitomycin C, either at a single 70-mg/m2 dose or at a dose of 20-30 mg/m2 once a week for 3 weeks. Two patients with adenocarcinoma among 21 evaluable patients with non-small cell carcinoma of the lung, and one with embryonal cell carcinoma among 21 patients with metastatic pulmonary tumors achieved partial response lasting 5 to 7 weeks. In these three patients, KW2083 was administered by a single 70-mg/m2 dose, and no patients who received a dose of 20-30 mg/m2 weekly achieved objective response. Myelosuppression, primarily thrombocytopenia, was pronounced with either treatment regimen and it was the major dose-limiting toxicity.

• Authors: T Shinkai, N Saijo, K Tominaga, K Eguchi, E Shimizu, Y Sasaki, J Fujita, H Futami, A Hoshi
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 15 Issue 1 Pg. 61-5 (Mar 1985) ISSN: 0368-2811 [Print] England
• PMID: 3981815 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Mitomycins
• Mitomycin
• 7-N-(4-hydroxyphenyl)mitomycin C

Topics

• Adult
• Aged
• Drug Evaluation
• Female
• Humans
• Lung Neoplasms (drug therapy, secondary)
• Male
• Middle Aged
• Mitomycin
• Mitomycins (adverse effects, therapeutic use)
• Thrombocytopenia (chemically induced)